03:47 AM EST, 12/09/2024 (MT Newswires) -- Genmab ( GMAB ) said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients with relapsed or refractory chronic lymphocytic leukemia.

Among all patients treated with the subcutaneously administered T-cell engaging antibody, median progression-free survival was 12.8 months and an estimated 65% were alive at 15 months, the Danish pharmaceutical company said.

Side effects of the treatment included cytokine release syndrome, diarrhea, edema, fatigue, and injection-site reaction, the company said.

Chronic lymphocytic leukemia is the most common leukemia.